Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
DTHe77MmvsP3ESzj
Listen
